Combination of Donafenib and Cytarabine/Daunorubicin in Relapsed AML
Study Details
Study Description
Brief Summary
This phase Ⅰ study of Donafenib, an oral multikinase inhibitor that targets Raf kinase and receptor tyrosine kinases, is to assess safety and pharmacokinetics in patients with Relapsed AML.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
| Phase 1 |
Detailed Description
Donafenib is a multikinase inhibitor which is acting on various cellular pathways involved in the genesis of acute myeloid leukemia (AML). Donafenib is therefore a promising candidate for improvement of chemotherapy results in AML. This clinical trial evaluates the safety and pharmacokinetics of Donafenib combination with Cytarabine/Daunorubicin for AML in patients between 18 and 55 years of age.
Study Design
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| Experimental: Donafenib, 0.2g Donafenib,0.2g,bid,Combination with Cytarabine and Daunorubicin. |
Drug: Donafenib
In first 28-days-cycle, eligible subjects will be given Donafenib 0.2/0.3g, bid, for first 14 days, combination with Daunorubicin 60mg/m2/d, for first 3 days, and Cytarabine 100mg/m2/d, for first 7 days. If CR or CRi is observed, subjects will be given Donafenib 0.2/0.3g, bid, for first 14 days, combination Cytarabine 2g/m2/q12h, for first 3 days, in next 28-day-cycle.
Other Names:
|
| Experimental: Donafenib,0.3g Donafenib,0.3g,bid,Combination with Cytarabine and Daunorubicin |
Drug: Donafenib
In first 28-days-cycle, eligible subjects will be given Donafenib 0.2/0.3g, bid, for first 14 days, combination with Daunorubicin 60mg/m2/d, for first 3 days, and Cytarabine 100mg/m2/d, for first 7 days. If CR or CRi is observed, subjects will be given Donafenib 0.2/0.3g, bid, for first 14 days, combination Cytarabine 2g/m2/q12h, for first 3 days, in next 28-day-cycle.
Other Names:
|
Outcome Measures
Primary Outcome Measures
- Safety(including the type, severity and frequency of AE) [through study completion, an average of 2 months]
Safety of combination of donafenib with Cytarabine/Daunorubicin in relapsed AML patients.
Eligibility Criteria
Criteria
Inclusion Criteria:
-
Patients with diagnosed AML (except APL) according to the FAB and WHO classification, including AML evolving from MDS or other hematologic diseases and AML after previous cytotoxic therapy or radiation (secondary AML) .
-
Patients with diagnosed Relapsed AML according to Chinese Guidelines for the Diagnosis and Treatment of Acute Myeloid Leukemia.
-
relapse after 6 months of an morphological remission.
-
Age ≥ 18 and ≤ 55 years.
-
BMI ≥ 18 and ≤27.
-
Informed consent, personally signed and dated to participate in the study.
-
ECOG performance status of 0-1.
-
Life expectancy of at least 12 weeks.
-
Total serum bilirubin ≤1.5×ULN.
-
Serum aspartate transaminase (AST) and/or alanine transaminase (ALT) ≤ 2.5×ULN.
-
Serum creatinine ≤1.5×ULN.
-
glomerular filtration rate ≥60 mL/min, as calculated with the Cockcroft-Gault formula.
-
alkaline phosphatase ≤1.5×ULN.
-
urine protein ≤1+, or Urine protein was quantified for 24h ≤0.5g.
-
INR/PTT <1.5×ULN.
Exclusion Criteria:
-
Patients who are not eligible for standard chemotherapy as per discretion of the treating physician.
-
Patients who have been treated with bone marrow transplantation.
-
Central nervous system manifestation of AML.
-
Cardiac disease: heart failure NYHA III or IV; unstable coronary artery disease (MI more than 6 months prior to study entry is permitted); serious cardiac ventricular arrhythmias requiring anti-arrhythmic therapy (beta blockers or digoxin are permitted).
-
Patients who have thrombosis events within 6 months prior to study entry is permitted.
-
Pregnancy or breastfeed.
-
Chronic pulmonary disease with relevant hypoxia.
-
Patients undergoing dialysis.
-
Known HIV and/or hepatitis C infection.
-
Evidence or history of severe non-leukemia associated bleeding diathesis or coagulopathy.
-
Evidence or recent history of CNS disease, including primary or metastatic brain tumors, seizure disorders.
-
Blood pressure (BP) higher than systolic 140 mmHg and/or diastolic 90 mmHg after best treatment.
-
Any severe concomitant condition which makes it undesirable for the patient to participate in the study or which could jeopardize compliance of the protocol.
-
Patients with major surgery, open biopsy or significant traumatic injury within 4 weeks prior to study entry is permitted.
-
Serious, non-healing wound, ulcer or bone fracture.
-
Infection need antibiotic treatment.
-
Cumulative therapeutic dose of Daunorubicin more than 300mg/m2.
-
Concurrent malignancies other than AML.
-
History of organ allograft.
-
Allergy to study medication or excipients in study medication.
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | Institute of Hematology and Blood Disease Hospital | Tianjin | Tianjin | China | 300020 |
Sponsors and Collaborators
- Suzhou Zelgen Biopharmaceuticals Co.,Ltd
Investigators
- Principal Investigator: Jianxiang Wang, Doctor, Institute of Hematology and Blood Disease Hospital
Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- ZGDAML1